Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Genentech, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to establish the feasibility and value of physical fitness assessment within patients receiving cytotoxic chemotherapy. If successful, this project will establish the groundwork for physical function assessment in larger cancer clinical trials to assist patient selection and evaluation of toxicity and/or response among trial participants.
Physical fitness, whether measured by performance capacity or daily activity, can predict risk of toxicity while helping to evaluate toxicity itself in the course of cancer chemotherapy. Cytotoxic chemotherapy causes premature aging and frailty in many cancer patients, so measuring and improving physical function may also limit late morbidity and mortality. Clinician-rated performance status (cPS; e.g., ECOG or Karnofsky PS) with or without concomitant organ function testing is the usual gold standard for risk prognostication and patient selection in most cancer settings, but cPS is subjective, unreliable, and relatively sensitive only for patients with significant functional compromise. Objective evaluations of physical function have the potential to augment or even replace cPS in the cancer treatment setting.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adjuvant and Curative Chemotherapy | 30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with adjuvant or curative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions. |
| |
| Palliative Chemoteraphy | 30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with palliative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biometric Devices | Device | Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy. |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients being approached that agree to participate in the study | Measure 1 for study feasibility | 12 months |
| Proportion of patients who complete both baseline and follow up CPET tests without significant testing-related adverse events | Measure 2 for study feasibility | 12 months |
| Proportion of patients who wear HealthPatch and have data captured successfully for at least 75% of the time | Measure 3 for study feasibility | 12 months |
| Patients who wear Philips Actiwatch and have data captured successfully for at least 75% of the time | Measure 4 for study feasibility | 12 months |
| Proportion of patients for whom all data is successfully recorded within the database | Measure 5 for study feasibility | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| VO2max measured both pre- and post-chemotherapy | Measured via cycle egometry | 12 months |
| 6 Minute Walk Distance (6MWD) | 12 months | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
60 patients with cancer undergoing a cycle of cytotoxic chemotherapy.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Natalie Grover, MD | University of North Carolina, Chapel Hill | Principal Investigator |
| William A Wood, MD | University of North Carolina, Chapel Hill | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27514 | United States |
Not provided
| Label | URL |
|---|---|
| UNC Lineberger Comprehensive Cancer Center | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Physical Performance Testing | Other | Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle. |
|
| Patient-reported sympotomatic toxicity and quality of life |
Measured using PROMIS, PRO-CTCAE, Godin Leisure Time Exercise questionnaires and Geriatric Assessment |
| 12 months |
| Patient activity/steps per day | Measured using Philips Actiwatch | 12 months |
| Heart rate | Continuous heart rate data, resting heart rate, and heart rate variability will be measured using HealthPatch | 12 months |
| Clinician-rated performance status | Clinician-rated ECOG and Karnofsky Performance Status (KPS) | 12 months |
| Incidence and number of falls | Measured by HealthPatch | 12 months |
| Sleep duration | Measured by Philips Actiwatch | 12 months |
| ID | Term |
|---|---|
| D019337 | Hematologic Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005080 | Exercise Test |
| ID | Term |
|---|---|
| D006334 | Heart Function Tests |
| D003935 | Diagnostic Techniques, Cardiovascular |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D012129 | Respiratory Function Tests |
| D003948 | Diagnostic Techniques, Respiratory System |
| D016552 | Ergometry |
| D008919 | Investigative Techniques |
Not provided
Not provided